Advice
following a full submission
bortezomib (Velcade®) is accepted for use within NHS Scotland.
Indication under review: in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone significantly improved progression-free survival compared to a regimen containing rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in adults with previously untreated mantle cell lymphoma who were unsuitable for haematopoietic stem cell transplantation.
Download detailed advice193KB (PDF)
Medicine details
- Medicine name:
- bortezomib (Velcade)
- SMC ID:
- 1075/15
- Indication:
- In combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 September 2015